Both neurotrophin-based therapy and neural stem cell (NSC)-based strategies have progressed to clinical trials for treatment of neurological diseases and injuries. Brain-derived neurotrophic factor (BDNF) in particular can confer neuroprotective and neuro-regenerative effects in preclinical studies, complementing the cell replacement benefits of NSCs.
Introduction
Following brain/spinal cord injury, the pathological microenvironment differs substantially from that of the normal endogenous tissue, with detrimental effects at the local tissue level, resulting in little or no tissue regeneration. Therefore, in order to stimulate neural repair, the injury microenvironment critically requires manipulation towards a pro-regenerative profile, through strategies such as induced expression of neurotrophins e.g. brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) [1] [2] [3] [4] . In this context, genetically engineered stem cell-based strategies offer both direct (donor cells for repopulation of lost cells) and indirect (support via secretion of neurotrophic factors) advantages to facilitate and accelerate cell repair and regeneration. This combinatorial approach (i.e. fusion of gene therapy and cell-based therapeutics) is considered to be an attractive and clinically relevant approach for repair of complex pathologies such as injuries of the brain and spinal cord [5] .
Of the heterogenous population of cells present in the central nervous system (CNS), neurons are particularly challenging to replace and repair following injury. BDNF has been widely validated as a therapeutic target given its beneficial effects in several neurological conditions such as Alzheimer's Disease, Parkinson's Disease, epilepsy and brain/spinal cord injuries [6, 7] . For example, intravenous BDNF administration has been shown to reduce infarct size of cerebral ischemia in a rat stroke model [8] . Intrathecal delivery of recombinant methionyl human BDNF for treatment of Amyotrophic Lateral Sclerosis has progressed to clinical trials, and appears to be well-tolerated and feasible. However, investigations of a sufficient number of cases is required before conclusions can be drawn regarding the clinical efficacy of this therapy [9] . These studies highlight the benefits of a combinatorial approach for neurological repair and neurorestoration; transplantation of genetically engineered NSCs can facilitate such an approach. Indeed, promising results were observed using cell-based therapies, for example, grafted BDNF-expressing NSCs in a murine model of stroke enhanced neurogenesis, showed neuroprotective properties (reduced apoptosis) and induced angiogenesis with functional recovery demonstrated by improved locomotor function [10] .
These BDNF delivery studies almost exclusively employ virus mediated gene delivery but safety and scale-up issues pose major barriers to the clinical translation of this approach [11] [12] [13] [14] . Non-viral magnetofection methods, using magnetic nanoparticles (MNPs) in conjunction A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 4 with oscillating magnetic fields can offer a safe solution for gene delivery in neural cells [15] [16] [17] [18] [19] [20] [21] [22] [23] but a major challenge encountered has been reduced transfection associated with increased size of therapeutic plasmids [23] [24] [25] [26] [27] (discussed in detail in Part I).
In this context, we have proved (using reporter gene sequences) that minicircles (mCs) are ideal DNA constructs for neural gene delivery in combination with magnetofection (see part I of manuscript). These mini-DNA vectors are devoid of the bacterial backbone structure typically present in all plasmid vectors (making them safer), but also increasing gene transfer efficacy (up to ca. 54%) due to their small size, both of critical importance for clinical translation. [28] We and others have reasoned that the superior transfection efficiency is likely due to mC engineered cells containing higher transgene copies per cell versus conventional plasmids. The mC vectors are also compliant with regulations on the use of medicinal products for gene transfer which restrict the use of selection markers due to their substantial potential to impact therapeutic outcomes [29] [30] [31] [32] [33] . Despite the obvious clinical translational benefits offered by this genetic modification methodology for regenerative neurology, the feasibility of mC based delivery of therapeutic genes to neural transplant populations has never been evaluated. Accordingly, the objectives of this study are to: (i) demonstrate the feasibility of using mC-functionalized MNPs for BDNF gene delivery into primary NSCs (ii) assess the safety profile of this approach, (iii) validate the short-term and long term functional effects of BDNF using an in vitro neuronal cell-based assay.
Methods

Materials
Cell culture reagents were obtained from Invitrogen and Sigma. Cell culture grade plastics were from Fisher Scientific. Human recombinant epidermal growth factor (EGF) and human BDNF Quantikine ELISA kit were from R&D Systems Europe Ltd. (Abingdon, UK). 
NSC culture
The care and use of all animals used in the production of cell cultures were in accordance with the Animals Scientific Procedures Act of 1986 (UK).
NSCs were generated from CD1 mice (postnatal days 1-3). Briefly, whole brains were harvested and the subventricular zone was microdissected, dissociated into a single-cell suspensions. NSCs were cultured as neurospheres (free floating cell clusters) in neurosphere medium (NS-M) comprising a DMEM:F12 (3:1 mix) containing B-27 supplement (2%), penicillin (50 U/ml), streptomycin (50 μg/ml), heparin (4 ng/ml), bFGF and EGF (20 ng/ml each). Neurospheres were fed every 2-3 days and passaged every 6 days using an Accutase-DNaseI mix.
Monolayer cultures
To prepare two-dimensional adherent NSC monolayers, neurospheres (passages 0 -2) were dissociated with accutase-DNase I, cells resuspended at 1.5 x 10 5 cells/ml monolayer culture medium (ML-M; comprising of a DMEM:F12 (1:1 mix) with N2 supplement (1%), penicillin (50 U/ml), streptomycin (50 μg/ml), heparin (4 ng/ml), FGF2 and EGF (20 ng/ml each).
NSCs were plated on polyornithine/laminin-coated coverslips in 24-well plates (0.6 ml suspension/well) and cultured at 37 ºC in 95% air:5% CO 2 .
NSC differentiation
NSCs were differentiated to the three major daughter cell types (neurons, astrocytes, oligodendrocytes) by replacing ML-M with differentiation medium (DF-M) consisting of NS-
M (without growth factors) and supplemented with fetal bovine serum (0.5%). Medium was changed every 2-3 days. Cells were maintained in the differentiated state for up to 4 weeks.
Construction of BDNF overexpression parental and mC DNA
A mC system was employed to address the influence of plasmid size and copy number on the 
Magnetofection of NSC cultures
For magnetofection experiments of NSC monolayers, medium was replaced with fresh ML-M (0.225 ml) before addition of transfection complexes. The particle-DNA complexes were prepared by mixing 170 ng of mC-BDNF-GFP and 0.62 µl Neuromag in 75 µl DMEM:F12
(1:1) base medium for each well. Following incubation for 20 min at room temperature (RT), the entire mixture was added to the cells. Plates were returned to the incubator, and exposed to a magnetic field using the magnefect-nano oscillating magnetic array system, with a 24magnet array (NdFeB, grade N42; field strength of 421 ± 20 mT) with an oscillating frequency of 4Hz (amplitude = 0.2 mm). The array moves laterally with oscillation frequency and amplitude controlled via a computerised motor. For single transfection, complexes were left for 48 h until fixation. For double transfection, the same protocol as above was followed, with a 24 h time window between the first and second transfection. Cells were either fixed (to assess transfection efficacy, 'stemness' and viability), or differentiated (to assess NSC differentiation potential) 48 h after the first transfection.
Immunocytochemistry
Paraformaldehyde-fixed cells were blocked (5% normal donkey serum in PBS-0.3% Triton-X-100) for 30 min at RT, followed by primary antibody incubation overnight at 4°C. The following antibodies (diluted in blocking solution) were added: Glial fibrillary protein (GFAP for astrocytes), 1:500, beta-Tubulin (Tuj1 for neurons), 1:1000, myelin basic protein (MBP for oligodendrocytes), 1:200 and GFP 1:1000. GFP immunostaining enhanced GFP detection in all cell types as previously reported (see manuscript part I). Secondary antibodies (either Cy3-or FITC-labelled) were diluted in blocking solution at 1:200 and were added to cells and incubated for 2h at RT. Following PBS washes, coverslips were mounted with Vectashield mounting medium containing DAPI.
Enzyme linked immunosorbent assay (ELISA)
At specific time points (48h, 5 days, 2 weeks and 4 weeks post transfection), the supernatant was collected, centrifuged (to remove cells and cell debris) and processed for ELISA. BDNF Neuronal morphometric quantification and analysis was carried out using NeuronJ. Neurite length was measured at the 2 week post-transfection time point, i.e. the condition at which neurites can be measured without interference from overlapping neurites. 
Statistical analyses
Results and Discussion
High purity of NSC primary cultures and DNA constructs encoding BDNF
promoter in cell lines derived from rodents, humans and macaques [34] [35] [36] . pp-BDNF-GFP was used to generate two circular DNA entities (i) mC DNA (mC-BDNF-GFP, Fig. 1A) which was purified for use in the study and (ii) the bacterial backbone which is excised and degraded during the process of mC induction. EcoRI and BamHI restriction digests of both constructs (Fig.1B) revealed the expected fragment sizes (the high molecular weight fragment corresponds to the vector and low molecular weight fragment corresponds to the BDNF insert) and also demonstrated the absence of parental plasmid contamination in the mC preparation. Comparable results were obtained from two separate preparations of mC-BDNF-GFP demonstrating the high reproducibility of the mC induction protocol employed in the study (Fig. 1B) . 
Minicircle DNA exhibits dramatically superior NSC transfection efficiencies compared to its corresponding parental plasmid
Immunostaining for GFP significantly enhanced protein detection as depicted in Fig. 2A; native GFP expression is shown in the inset. Therefore all samples were processed for GFP for protein synthesis and packaging (Fig. 2C ) [37] . Double transfection (multifection) was carried out in all experiments as it results in higher transfection efficiencies than single transfection in experiments using reporter plasmids [38] . NSCs multifected with mC-BDNF-GFP reported higher transfection efficiencies compared to pp-BDNF-GFP (transfection efficiency range 28.9 -21.8% vs 4.4 -3.9% respectively) ( Fig.2 D -F ). Having determined that BDNF is expressed within cells, BDNF secretion was verified at 24 hours following the second transfection. mC-BDNF-GFP engineered cells showed approximately a 20-fold increase in secretion levels compared to untransfected NSCs (Fig. 2G ). In comparison, pp-BDNF-GFP transfection resulted in a two-fold increase in BDNF secretion. 
BDNF overexpression promotes NSC proliferation
BDNF overexpression resulted in a significant increase in NSC number compared to nontransfected cells as judged by DAPI staining (average cell number per field: 224 ± 14 for untransfected vs 288 ± 12 for mC-BDNF-GFP) (Fig. 3A, B and G ). An increased number of Ki-67 + NSCs was observed in parallel in the mC-BDNF-GFP condition compared to untransfected counterparts (Fig. C-F and H) . It is important to note that the NSC monolayer media contains both EGF and bFGF implying that in combination with these mitogenic factors, BDNF may have a synergistic effect on NSC proliferation [39] . Due to this overall proliferative effect of BDNF on NSCs, the actual transfection efficiency reported here is therefore likely to be an underestimate of the initial transfection levels. The result here demonstrates the functional effects of the encoded BDNF as it is known to be involved in NSC proliferation, among many other cellular processes such as neural differentiation and maturation [40] . Our study shows that the BDNF levels induced are sufficient to have a functional biological effect on NSCs. As an example, transplantation of a mixed population of VEGF-engineered NSCs (transduction efficiency of ca 20-30% obtained in this study) demonstrated neuroprotective effects and increased angiogenesis in intact non-disease brains [41] . The proliferative effects of BDNF on NSCs can be predicted to be advantageous for ex vivo gene therapy, resulting in genesis of increased numbers of progenitor populations that can in turn result in enhanced production of neurons [40] . While such enhanced division does
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ACCEPTED MANUSCRIPT 13 raise issues related to safety of the procedures, we consider that the observed enhancement of proliferation is unlikely to be an issue of major clinical concern given that the default fate of NSCs has repeatedly been shown to be differentiation towards the neuronal and glial phenotypes, along with a loss of proliferative capacity [42] . However, this will need to be robustly tested using transplantation of mC engineered neural transplant cells delivered to in vivo models of neurological injury. 
mC-BDNF-GFP engineered NSCs exhibit normal cell stemness and viability
No observable differences in cell morphology and adherence were identified between the untransfected and mC-BDNF-GFP transfected conditions. Normal bipolar cell morphologies with round nuclei were observed indicating healthy cells (Fig. 4A ) under both conditions.
Quantification of propidium iodide (a fluorescent marker for cell death) stained nuclei (indicated by arrows in Fig. 4A ) demonstrated no differences in cell viability between the two conditions ( Fig. 4B ). Transfected NSCs also retained their stem cell specific marker expression profile for Nestin, a cytoskeletal protein (Fig. 4C ) similar to untransfected cells ( Fig. 4D) . Similarly assessment of another marker for undifferentiated stem cells, Sox2 transcription factor (Fig.4E ) showed no differences in the proportions of Sox2 + cells between the two groups (Fig. 4F) . These results demonstrate that NSC multifection with mC-BDNF-GFP does not affect NSC cellular health and physiology. We consider that this high safety profile is of critical importance, as evidenced here and in our previous study (see manuscript part I), emphasizing the translational potential of mC mediated engineering for cell-based therapies. Although BDNF is known to drive differentiation towards neuronal phenotypes, our data suggests that BDNF in the presence of mitogenic factors which maintain pluripotency such as EGF and bFGF (present at high concentration in the media) does not induce differentiation [43] . 
The differentiation potential of BDNF transfected NSCs is skewed towards increased neurogenesis
Following transplantation in vivo, it is well established that NSCs spontaneously differentiate into neuronal and glial lineages [38] . Following multifection, NSCs were induced to differentiate (by removal of growth factors from the medium) in order to examine the potential of NSCs to give rise to the three main daughter cell types (neurons, astrocytes and oligodendrocytes; the relative cell proportions usually generated are ca. 20%, 75% and 5% respectively). Microscopic assessment of the daughter cells showed normal morphologies, adherence and staining profiles. Untransfected NSCs generated ca. 18% neurons while BDNF engineered NSCs showed approximately two-fold increase in neurons generated (up to ca. 38%) ( Fig. 5A-C) . A previous study using SVZ-derived NSCs from rats reported that addition of BDNF in the media generated a marked increase (approximately 14-fold) in the number of neurons (2.6% vs 35.3%, control vs BDNF-containing differentiation media) [44] .
It is important to note that the amount of BDNF administered in the previous study was 10ng/ml, ~10x higher than the concentration measured from the media supernatants in our study (ca.1ng/ml). Our data is in line with previous studies where BDNF induction led to a two-fold increase in neuronal numbers [45] . A possible explanation for this phenomenon is that the presence of BDNF influences the fate of these uncommitted progenitor cells, therefore favouring differentiation towards neurons [45] . Moreover, several studies have also reported that BDNF promotes the survival of neurons, which could account for the significant increase in neuronal numbers in the mC-BDNF-GFP condition [46] [47] [48] .
In parallel with increased genesis of neurons, the number of astrocytes generated was reduced significantly while oligodendrocyte numbers were similar between the two groups in our study ( Fig. 5C ). Of the differentiated progeny, astrocytes were the predominant GFP + cell types (Fig.5D ) as reported earlier (see manuscript part I) [49] [50] [51] . GFP expression was colocalised with extensive BDNF expression within cells (Fig. 5E ). Neurons (Fig. 5F ) and oligodendrocytes (Fig.5G) were rarely observed to be GFP + . This finding is in contrast to our previous report using magnetofection/mC mediated reporter gene delivery using mC-GFP which resulted in relatively higher numbers of GFP + neurons and oligodendrocytes. This highlights the potential significance of using smaller size DNA vectors for cell specific transfection since mC-GFP (1.5kb in size) is approximately 2.6 smaller than mC-BDNF-GFP (4kb) used in this study. These findings also highlight the importance of using separate mC
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BDNF overexpression enhances neurite outgrowth
Augmented BDNF levels also resulted in enhanced neurite outgrowth. The need for accelerated neurite outgrowth is key as mature neurons are required in order to facilitate the establishment and integration of functional neuronal networks with the host tissue. [52] Morphological observations showed obvious differences in neurite length at the 2 week and 4
week time points ( Fig. 6 A-B , D-E). Neurite length assessments were carried out at the 2
week time point as optimal measurements for neurite length were obtained for both conditions (i.e. no overlapping neurites). Neurite length was dramatically increased in mC-BDNF-GFP treated cells compared to untransfected cells (Fig. 6C ). Experimental evidence of BDNF-mediated neurite outgrowth has been shown in both NSC derived neurons as well as mature neuronal cultures [45, 53] . Though BDNF levels continually decreased over the four
week time period (Fig. 6F) , it is important to note that this is an underrepresentation of in vivo BDNF levels as media was changed every few days, therefore diluting the actual BDNF levels in this in vitro assay. In the case of therapeutic gene delivery, a tapered profile of therapeutic expression is favoured following transplantation as (i) the functional outcome can be achieved early on i.e. increased neuronal number and enhanced maturation (ii) molecular expression of neurotrophic factors profiles change over time therefore reducing the need for specific therapeutic factors. 
Clinical implications of minicircle/magnetofection engineered NSCs expressing BDNF for regenerative neurology
This is the first demonstration of mC technology used in conjunction with MNPs for delivery of a neurotherapeutic biomolecule. Using reporter gene sequences, we previously suggested that such an approach could be of high clinical relevance in terms of safety, transfection efficiency and sustained gene transfer (Part I). The target protein, BDNF, is a major therapeutic candidate for a number of neurological disorders and injuries such Alzheimer's disease, stroke and spinal cord injury as demonstrated in rodent and primate preclinical models [6, [54] [55] [56] . The CNS has a limited capacity to generate neurons following injury, as the microenvironment within the site of pathology is unfavourable for the survival and differentiation of neurons. BDNF overexpression (through the paracrine effect conferred by the predominantly engineered astrocytic population) can address this issue in three ways. 1) generation of higher neuronal numbers 2) neuroprotection of differentiated neurons and 3) accelerated levels of neuronal maturation. We show the potential of mC-engineered NSCs to contribute to such regenerative events, findings that are in line with several in vitro, ex vivo and in vivo studies. We consider the combination of approaches used here to be safer, costeffective and less time-consuming for the clinic, in comparison to viral-mediated gene delivery approaches and systemic BDNF administration. Further, neurotrophin production has high manufacturing costs [57] and systemic neurotrophic factor administration including BDNF has been shown to be less efficient as only a small amounts of the protein can cross the blood brain barrier and can result in undesirable side effects. [58] Given the pathologyhoming nature of NSCs towards a site of injury, our combinatorial approach could enable a more localised delivery of the therapeutic gene enabling in situ biomolecule expression. In the context of improved safety and efficacy of gene delivery, the entire mC construct used in this study is biocompatible including the promoter (human EF1a) as opposed to the widely used virus-derived promoters such as CMV. Additionally, using mCs without the reporter gene (further reducing size) could enable much higher and sustained levels.
Accelerated and effective functional therapeutic outcomes require delivery of multiple genes simultaneously. For example, to further increase neuronal yield, a combination of BDNF, b-FGF and IGF1 may be required [59] . The mC system can enable a versatile yet flexible therapeutic approach in which a number of different neurotrophic factors can be delivered simultaneously to NSCs in order to achieve optimal therapeutic outcome in vivo [23] . This is especially pertinent in the context of addressing the complexity of neural pathology where a combinatorial therapy can also allow multiple genes to be expressed simultaneously to address multiple regenerative targets, in other words a 'molecular cocktail'. As an example, these could include BDNF for axonal outgrowth, chondroitinase ABC for breakdown of repair-inhibitory matrix glycoproteins and VEGF to promote cell survival and angiogenesis (potentially via use of multicistronic plasmids), without greatly increasing vector size. We have previously demonstrated that MNPs can mediate delivery of two different reporter genes (GFP and RFP) to NSC neurospheres and monolayers (with up to 90% of transfected cells co-expressing both markers) [23] indicating that delivery of multiple therapeutic genes using
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Further advantages of our approach have been discussed previously (see manuscript Part I).
Briefly, both mCs and MNPs can be economically produced at a large scale at high purity with the development of novel technologies such as affinity-based chromatographic purification and flame spray method [60, 61] . Additionally, the robust one-step protocol used here requires minimal training and basic laboratory equipment/containment level.
mC/magnetofection technology could be also be exploited for the delivery of recombinant proteins such as Tau-neutralising antibodies [62] , the prevalent component in neurofibrillary tangles, brain-penetrating biologic TNF-inhibitor in Parkinson's disease [63] and other emergent biologics currently being developed for effective neuro-therapeutics.
Conclusion
Our findings provide the first proof that mC DNA vectors in conjunction with nanoparticle carriers, can mediate delivery of a gene encoding a major neurotrophic factor, BDNF, which enhances neurogenesis and exerts neuroprotective effects. The mC DNA vector system allows for the restrictions imposed by increased plasmid size (leading to decreased nanoparticle-mediated cellular transfection) to be reduced. Our procedures were associated with high safety, and clear neuroregenerative outcomes could be observed in terms of increased genesis of neurons/enhanced neuronal maturation, consistent with the reported role of BDNF. Based on these findings, we consider that a fusion of mC DNA vector technology with nanoparticle vehicles significantly enhances the functionality of nanoparticle vector platforms, and could come to represent the genetic modification method of choice for clinical cell therapies. Additionally, given the progression of both neurotrophins and NSCs to clinical trials, we suggest that mC based engineering for translational applications appears realistic.
